FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2417800002> ?p ?o ?g. }

• W2417800002 endingPage "729" @default.
• W2417800002 startingPage "717" @default.
• W2417800002 abstract "Background Whether or not second-generation antipsychotics (SGAs) represent an advantage over first-generation antipsychotics (FGAs) in the treatment of schizophrenia is not certain. Effectiveness studies published in the past 10 years have not unequivocally confirmed the superiority of SGAs over FGAs. We aimed to compare quality of life in patients with schizophrenia on an FGA strategy with those on an SGA strategy. Methods In the multicentre, randomised, double-blind Neuroleptic Strategy Study (NeSSy), we recruited participants (aged 18–65 years) with schizophrenia (ICD-10: F20.X) who required treatment initiation or a change in treatment, from 14 psychiatric university hospitals and state hospitals in Germany. Double randomisation allowed for restricted selection of a treatment within each antipsychotic drug group (FGA or SGA) for an individual patient: first, patients were assigned with a random number table to two of six possible drug pairs, each pair consisting of an FGA (haloperidol [3–6 mg] or flupentixol [6–12 mg]) given orally and an SGA (aripiprazole [10–20 mg], olanzapine [10–20 mg], or quetiapine [400–800 mg]) given orally, and the investigator then selected which pair was best suited to the patient; a second, double-blind random assignment allocated either the FGA or the SGA from the investigator-chosen pair to the patient. Treatment duration was 24 weeks. Primary outcomes were change from baseline to week 24 in quality of life (SF-36) and clinical global impression (CGI-I), analysed in all randomly assigned patients who received at least one dose of the study drug. Safety was assessed in a safety set, consisting of all randomly assigned patients who received at least one dose of the study drug, coinciding with the set of the efficacy analyses. The study is registered with ClinicalTrials.gov, number NCT01164059; German Clinical Trials Register, number DRKS00000304; WHO ICTRP, number U1111–1112–9727; and EudraCT, number 2009–010966–47. Findings Between April 1, 2010, and May 31, 2013, 149 patients were randomly assigned, 69 to FGA treatment and 80 to SGA treatment. 136 patients received at least one dose of study drug (63 in the FGA group, 73 in the SGA group). Mean area under the curve (AUC) values of SF-36 were significantly higher in the SGA group than in the FGA group (85·1 [SD 14·7] vs 79·7 [17·3], p=0·0112). Mean AUC values for CGI-I scores decreased in both groups, but were not significantly different between the two groups (3·39 [SD 0·89] in the FGA group vs 3·26 [0·92] in the SGA group, p=0·3423). 30 (48%) of 63 patients given FGAs had at least one adverse event compared with 42 (57%) of 73 patients given an SGA (p=0·3019); the most common were nervous system disorders (18 [60%] of 30 in the FGA group vs 19 [45%] of 42 in the SGA group) and psychiatric disorders (ten [33%] vs 16 [38%]). One patient died after cessation of study drug (olanzapine), most likely as a result of an illicit drug overdose. The increase in body-mass index (BMI) was significantly higher in the SGA group than in the FGA group (p=0·0021 at week 6 and p=0·0041 at week 24). Interpretation Improvement of patient-reported quality of life was significantly higher in patients with schizophrenia given SGAs than in those given FGAs, when treatment selection was individualised. This advantage, however, has to be weighed against the potential metabolic adverse effects of some SGAs. Funding German Federal Ministry of Education and Research." @default.
• W2417800002 created "2016-06-24" @default.
• W2417800002 creator A5009642804 @default.
• W2417800002 creator A5027556916 @default.
• W2417800002 creator A5028100180 @default.
• W2417800002 creator A5048529972 @default.
• W2417800002 creator A5051340444 @default.
• W2417800002 creator A5066333002 @default.
• W2417800002 creator A5069833255 @default.
• W2417800002 creator A5081339058 @default.
• W2417800002 date "2016-08-01" @default.
• W2417800002 modified "2023-10-06" @default.
• W2417800002 title "Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study" @default.
• W2417800002 cites W1972366325 @default.
• W2417800002 cites W1974369180 @default.
• W2417800002 cites W1986678216 @default.
• W2417800002 cites W1994840924 @default.
• W2417800002 cites W2011099157 @default.
• W2417800002 cites W2028067695 @default.
• W2417800002 cites W2030017858 @default.
• W2417800002 cites W2041474698 @default.
• W2417800002 cites W2060417841 @default.
• W2417800002 cites W2070427088 @default.
• W2417800002 cites W2081069399 @default.
• W2417800002 cites W2085360366 @default.
• W2417800002 cites W2087310251 @default.
• W2417800002 cites W2099704493 @default.
• W2417800002 cites W2106156723 @default.
• W2417800002 cites W2108022657 @default.
• W2417800002 cites W2109196233 @default.
• W2417800002 cites W2111883919 @default.
• W2417800002 cites W2125138227 @default.
• W2417800002 cites W2140606211 @default.
• W2417800002 cites W2141895509 @default.
• W2417800002 cites W2144676612 @default.
• W2417800002 cites W2149639459 @default.
• W2417800002 cites W2152770536 @default.
• W2417800002 cites W2159039084 @default.
• W2417800002 cites W2159155203 @default.
• W2417800002 cites W2161414087 @default.
• W2417800002 cites W2168875379 @default.
• W2417800002 cites W2172273501 @default.
• W2417800002 cites W2312852837 @default.
• W2417800002 cites W2412121580 @default.
• W2417800002 cites W4230257729 @default.
• W2417800002 cites W4244847179 @default.
• W2417800002 cites W4249129014 @default.
• W2417800002 doi "https://doi.org/10.1016/s2215-0366(16)00085-7" @default.
• W2417800002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27265548" @default.
• W2417800002 hasPublicationYear "2016" @default.
• W2417800002 type Work @default.
• W2417800002 sameAs 2417800002 @default.
• W2417800002 citedByCount "50" @default.
• W2417800002 countsByYear W24178000022016 @default.
• W2417800002 countsByYear W24178000022017 @default.
• W2417800002 countsByYear W24178000022018 @default.
• W2417800002 countsByYear W24178000022019 @default.
• W2417800002 countsByYear W24178000022020 @default.
• W2417800002 countsByYear W24178000022021 @default.
• W2417800002 countsByYear W24178000022022 @default.
• W2417800002 countsByYear W24178000022023 @default.
• W2417800002 crossrefType "journal-article" @default.
• W2417800002 hasAuthorship W2417800002A5009642804 @default.
• W2417800002 hasAuthorship W2417800002A5027556916 @default.
• W2417800002 hasAuthorship W2417800002A5028100180 @default.
• W2417800002 hasAuthorship W2417800002A5048529972 @default.
• W2417800002 hasAuthorship W2417800002A5051340444 @default.
• W2417800002 hasAuthorship W2417800002A5066333002 @default.
• W2417800002 hasAuthorship W2417800002A5069833255 @default.
• W2417800002 hasAuthorship W2417800002A5081339058 @default.
• W2417800002 hasConcept C118552586 @default.
• W2417800002 hasConcept C126322002 @default.
• W2417800002 hasConcept C142724271 @default.
• W2417800002 hasConcept C15744967 @default.
• W2417800002 hasConcept C159110408 @default.
• W2417800002 hasConcept C187212893 @default.
• W2417800002 hasConcept C204787440 @default.
• W2417800002 hasConcept C27081682 @default.
• W2417800002 hasConcept C2776000289 @default.
• W2417800002 hasConcept C2776412080 @default.
• W2417800002 hasConcept C2776619155 @default.
• W2417800002 hasConcept C2779951463 @default.
• W2417800002 hasConcept C2780057945 @default.
• W2417800002 hasConcept C2780211496 @default.
• W2417800002 hasConcept C2780494398 @default.
• W2417800002 hasConcept C2780634440 @default.
• W2417800002 hasConcept C71924100 @default.
• W2417800002 hasConceptScore W2417800002C118552586 @default.
• W2417800002 hasConceptScore W2417800002C126322002 @default.
• W2417800002 hasConceptScore W2417800002C142724271 @default.
• W2417800002 hasConceptScore W2417800002C15744967 @default.
• W2417800002 hasConceptScore W2417800002C159110408 @default.
• W2417800002 hasConceptScore W2417800002C187212893 @default.
• W2417800002 hasConceptScore W2417800002C204787440 @default.
• W2417800002 hasConceptScore W2417800002C27081682 @default.
• W2417800002 hasConceptScore W2417800002C2776000289 @default.
• W2417800002 hasConceptScore W2417800002C2776412080 @default.
• W2417800002 hasConceptScore W2417800002C2776619155 @default.

• next